Resources from the same session
Optimal combinations of systemic therapies in treatment-naïve patients with advanced hormone-sensitive prostate cancer: Which ones and for which patients?
Presenter: Arnulf Stenzl
Session: ESMO Colloquium supported by Astellas Pharma Singapore Pte. Ltd.: Optimising outcomes of patients with advanced prostate and urothelial cancer
Resources:
Slides
Webcast
How do modern first-line combination regimens affect the therapeutic algorithm in later lines of therapy in metastatic prostate cancer?
Presenter: Karim Fizazi
Session: ESMO Colloquium supported by Astellas Pharma Singapore Pte. Ltd.: Optimising outcomes of patients with advanced prostate and urothelial cancer
Resources:
Slides
Webcast
State of the art therapeutic landscape in non-metastatic castration-resistant prostate cancer
Presenter: Wai Kay Kwong
Session: ESMO Colloquium supported by Astellas Pharma Singapore Pte. Ltd.: Optimising outcomes of patients with advanced prostate and urothelial cancer
Resources:
Slides
Webcast
Emerging systemic therapies in unresectable bladder cancer: Immunotherapy, kinase inhibitors and antibody-drug conjugates
Presenter: Matthew Galsky
Session: ESMO Colloquium supported by Astellas Pharma Singapore Pte. Ltd.: Optimising outcomes of patients with advanced prostate and urothelial cancer
Resources:
Slides
Webcast